EGI
GTHX

EAM Global Investors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

EAM Global Investors’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-133,203
Closed -$1.66M – 248
2022
Q3 		$1.66M Buy
+133,203
New +$1.52M 0.44% 111
2019
Q3 		– Sell
-43,584
Closed -$1.34M – 152
2019
Q2 		$1.34M Buy
+43,584
New +$918K 0.57% 103
2018
Q2 		– Sell
-28,713
Closed -$1.06M – 190
2018
Q1 		$1.06M Buy
+28,713
New +$766K 0.55% 97

Other funds holding GTHX

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

EAM Global Investors's GTHX Position: Q4 2022 in Review

EAM Global Investors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2022, closing a stake of 133,203 shares — an estimated $1.66M sold.

EAM Global Investors first reported a position in GTHX in Q1 2018 and held it in 3 quarters. The position peaked at $1.66M in Q3 2022. 116 funds tracked by Wall St. Rank hold GTHX as of Q4 2022.

  • EAM Global Investors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • EAM Global Investors sold 133,203 G1 Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $1.66M.
  • EAM Global Investors first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
  • EAM Global Investors's G1 Therapeutics, Inc. Common Stock position peaked at $1.66M in Q3 2022.
  • 116 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2022.

Based on EAM Global Investors's 13F filing for Q4 2022, filed 14 Feb 2023.